Homocysteine exerts cell type-specific inhibition of AP-1 transcription factor

Free Radical Biology and Medicine

Volumn 28, Issue 1, 2000, Pages 39-45

  Suzuki, Yuichiro J ^a,b   Lorenzi, Matthew V ^c   Shi, Susan S ^a   Day, Regina M ^d   Blumberg, Jeffrey B ^a,b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

AP 1; Free radicals; Gene expression; Homocysteine; Redox; Signal transduction; Thiols

Indexed keywords

FREE RADICAL; HOMOCYSTEINE; HOMOCYSTINE; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; THIOLACTONE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE EXPRESSION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

3T3 CELLS; ANIMALS; CELL DIVISION; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, FOS; GENES, IMMEDIATE-EARLY; GENES, JUN; GENES, RAS; HOMOCYSTEINE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MUSCLE, SMOOTH, VASCULAR; NUCLEAR PROTEINS; ORGAN SPECIFICITY; OXIDATION-REDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 0033958113     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00200-2     Document Type: Article

References (31)

1. McCully K.S. Homocysteine and vascular disease. Nature Med. 2:1996;386-389.
2. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., Graham I. Hyperhomocysteinemia an independent risk factor for vascular disease . N. Engl. J. Med. 324:1991;1149-1155.
3. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
4. Perry I.J., Refsum H., Morris R.W., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
5. Selhub J., Jacques P.F., Bostom A.G., D'agostino R.B., Wilson P.W.F., Belanger A.J., O'Leary D.H., Wolf P.A., Schaefer E.J., Rosenberg I.H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332:1995;286-291.
6. Olszewski A.J., McCully K.S. Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic. Biol. Med. 14:1993;683-693.
7. Roubenoff R., Dellaripa P., Nadeau M.R., Abad L.W., Muldoon B.A., Selhab J., Rosenberg I.H. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 40:1997;718-722.
8. Glynn S.A., Albanes D., Pietinen P., Brown C.C., Rautalahti M., Tangrea J.A., Gunter E.W., Barrett M.J., Virtama J., Taylor P.R. Colorectal cancer and folate status a nested case-control study among male smokers . Cancer Epidemiol. Biomark. Prevent. 5:1996;487-494.
9. Moustapha A., Naso A., Nahlawi M., Gupta A., Arheart K.L., Jacobsen D.W., Robinson K., Dennis V.W. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 97:1998;138-141.
10. Nygard O., Vollset S.E., Refsum H., Stensvold I., Tverdal A., Nordrehaug J.E., Ueland P.M., Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA. 274:1995;1526-1533.
11. Tsai J.-C., Perrella M.A., Yoshizumi M., Hsieh C.-M., Haber E., Schlegel R., Lee M.-E. Promotion of vascular smooth muscle cell growth by homocysteine a link to atherosclerosis . Proc. Natl. Acad. Sci. USA. 91:1994;6369-6373.
12. Dalton M.L., Gadson P.F. Jr, Wrenn R.W., Rosenquist T.H. Homocysteine signal cascade production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells . FASEB J. 11:1997;703-711.
13. Turner R., Tjian R. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science. 243:1989;1689-1694.
14. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:1997;240-246.
15. Pennypacker K.R., Hong J.-S., McMillian M.K. Pharmacological regulation of AP-1 transcription factor DNA binding activity. FASEB J. 8:1994;475-478.
16. ras methylation in vascular endothelial cells by homocysteine but not cysteine. J. Biol. Chem. 272:1997;25380-25385.
17. Day R.M., Cioce V., Breckenridge D., Castagnino P., Bottaro D.P. Differential signaling by alternative HGF isoforms through c-Met activation of both MAP kinase and PI 3-kinase pathways is insufficient for mitogenesis . Oncogene. 18:1999;3399-3406.
18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
19. Suzuki Y.J., Packer L. A rapid method for studying the redox regulation of DNA-protein interactions by biothiols. Methods Enzymol. 252:1995;175-180.
20. Tolkacheva T., Feuer B., Lorenzi M.V., Saez R., Chan A.M. Cooperative transformation of NIH/3T3 cells by G alpha12 and Rac1. Oncogene. 15:1997;727-735.
21. Kimmelman A., Tolkacheva T., Lorenzi M.V., Osada M., Chan A.M. Identification and characterization of R-ras3 a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution . Oncogene. 15:1997;2675-2685.
22. Hunter T. Oncoprotein networks. Cell. 88:1997;333-346.
23. Davis R.J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:1993;14553-14556.
24. Payne D.M., Rossomando A.J., Martino P., Erickson A.K., Her J.H., Shabanowitz J., Hunt D.F., Weber M.J., Sturgill T.W. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10:1991;885-892.
25. Robbins D.J., Cheng M., Zhen E., Vanderbilt C.A., Feig L.A., Cobb M.H. Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc. Natl. Acad. Sci. USA. 89:1992;6924-6928.
26. Feig L.A., Cooper G.M. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol. 8:1988;3235-3243.
27. Stacey D.W., Roudebush M., Day R., Mosser S.D., Gibbs J.B., Feig L.A. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes. Oncogene. 6:1991;2297-2304.
28. Treisman R. Ternary complex factors growth factor regulated transcriptional activators . Curr. Opin. Genet. Dev. 4:1994;96-101.
29. Abate C., Patel L., Rauscher F.J. III, Curran T. Redox regulation of Fos and Jun DNA-binding activity in vitro. Science. 249:1990;1157-1161.
30. Xanthoudakis S., Curran T. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J. 11:1992;653-665.
31. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA. 94:1997;3633-3638.